IP Library › Granted Patent US 12,230,364
Granted Patent B2
US 12,230,364 · App. 18/186,762 · Granted Feb 18, 2025

Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

Inventor: Wei Keat Lim (Tarrytown, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
G16B30/00A61P35/00C12Q1/6806C12Q1/6809C12Q1/6886G16B5/00G16B15/00C12Q2565/519C12Q2600/106C12Q2600/156C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,230,364
App. No.
18/186,762
Granted
Feb 18, 2025
Kind
B2
Abstract

Methods for selecting a cancer patient for immunotherapy comprise establishing a total passenger gene mutation burden from a tumor of a cancer patient, generating a background distribution for the mutational burden of the tumor, normalizing the total passenger gene mutation burden against the background distribution, and categorizing the cancer patient as an immunotherapy responder when the total passenger gene mutation burden is greater than the mean of the background distribution. When the cancer patient is an immunotherapy responder, the patient may be administered an immunotherapy regimen that comprises activation/inhibition of T cell receptors that promote T cell activation and/or prolong immune cytolytic activities.

Claims (48)

1. A method of treating a cancer patient with an antibody that binds to LAG3, comprising administering the antibody that binds to LAG3 to the cancer patient, whereby the cancer patient has been determined to have a tumor having a total passenger gene mutational burden that is greater than a background mutational burden of the tumor.

2. The method according to claim 1 , wherein the background mutational burden is determined based on randomly selected genes of the tumor, and wherein a number of the randomly selected genes is equal to a number of passenger genes used to determine the total passenger gene mutational burden.

3. The method according to claim 1 , wherein the total passenger gene mutational burden is determined based on one or more passenger genes having a genetic mutation rate that is highly correlated with overall tumor mutation frequencies.

4. The method according to claim 1 , wherein the cancer comprises a skin cancer, a lung cancer, or a blood-derived cancer.

5. The method according to claim 4 , wherein the skin cancer comprises melanoma or cutaneous squamous cell cancer.

6. The method according to claim 4 , wherein the lung cancer comprises lung adenocarcinoma, lung squamous cell carcinoma, or non-small cell lung carcinoma.

7. The method according to claim 4 , wherein the blood-derived cancer comprises leukemia or acute myeloid leukemia.

8. The method according to claim 1 , wherein the cancer comprises melanoma.

9. The method according to claim 1 , wherein the cancer comprises non-small cell lung carcinoma.

10. The method according to claim 1 , wherein the antibody that binds to LAG3 comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 93.

11. The method according to claim 10 , wherein the cancer comprises a skin cancer, a lung cancer, or a blood-derived cancer.

12. The method according to claim 11 , wherein the skin cancer comprises melanoma or cutaneous squamous cell cancer.

13. The method according to claim 11 , wherein the lung cancer comprises lung adenocarcinoma, lung squamous cell carcinoma, or non-small cell lung carcinoma.

14. The method according to claim 11 , wherein the blood-derived cancer comprises leukemia or acute myeloid leukemia.

15. The method according to claim 10 , wherein the cancer comprises melanoma.

16. The method according to claim 10 , wherein the cancer comprises non-small cell lung carcinoma.

17. The method according to claim 1 , wherein the passenger gene mutational burden is determined to be greater than the background mutational burden by:

establishing the total passenger gene mutational burden of the tumor;

generating the background mutational burden; and

normalizing the total passenger gene mutational burden against the background mutational burden.

18. The method according to claim 1 , the method further comprising administering an antibody that binds to PD1 to the cancer patient.

19. The method according to claim 18 , wherein the cancer comprises a skin cancer, a lung cancer, or a blood-derived cancer.

20. The method according to claim 19 , wherein the skin cancer comprises melanoma or cutaneous squamous cell cancer.

21. The method according to claim 19 , wherein the lung cancer comprises lung adenocarcinoma, lung squamous cell carcinoma, or non-small cell lung carcinoma.

22. The method according to claim 19 , wherein the blood-derived cancer comprises leukemia or acute myeloid leukemia.

23. The method according to claim 18 , wherein the cancer comprises melanoma.

24. The method according to claim 18 , wherein the cancer comprises non-small cell lung carcinoma.

25. The method according to claim 18 , wherein the antibody that binds to PD1 comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 21.

26. The method according to claim 25 , wherein the cancer comprises a skin cancer, a lung cancer, or a blood-derived cancer.

27. The method according to claim 26 , wherein the skin cancer comprises melanoma or cutaneous squamous cell cancer.

28. The method according to claim 26 , wherein the lung cancer comprises lung adenocarcinoma, lung squamous cell carcinoma, or non-small cell lung carcinoma.

29. The method according to claim 26 , wherein the blood-derived cancer comprises leukemia or acute myeloid leukemia.

30. The method according to claim 25 , wherein the cancer comprises melanoma.

31. The method according to claim 25 , wherein the cancer comprises non-small cell lung carcinoma.

32. The method according to claim 18 , wherein the antibody that binds to PD1 comprises cemiplimab.

33. The method according to claim 32 , wherein the cancer comprises a skin cancer, a lung cancer, or a blood-derived cancer.

34. The method according to claim 33 , wherein the skin cancer comprises melanoma or cutaneous squamous cell cancer.

35. The method according to claim 33 , wherein the lung cancer comprises lung adenocarcinoma, lung squamous cell carcinoma, or non-small cell lung carcinoma.

36. The method according to claim 33 , wherein the blood-derived cancer comprises leukemia or acute myeloid leukemia.

37. The method according to claim 32 , wherein the cancer comprises melanoma.

38. The method according to claim 32 , wherein the cancer comprises non-small cell lung carcinoma.

39. The method according to claim 1 , wherein the antibody that binds to LAG3 comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 94.

40. The method according to claim 39 , wherein the cancer comprises a skin cancer, a lung cancer, or a blood-derived cancer.

41. The method according to claim 40 , wherein the skin cancer comprises melanoma or cutaneous squamous cell cancer.

42. The method according to claim 40 , wherein the lung cancer comprises lung adenocarcinoma, lung squamous cell carcinoma, or non-small cell lung carcinoma.

43. The method according to claim 40 , wherein the blood-derived cancer comprises leukemia or acute myeloid leukemia.

44. The method according to claim 39 , wherein the cancer comprises melanoma.

45. The method according to claim 39 , wherein the cancer comprises non-small cell lung carcinoma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2023
From: LIM, WEI KEAT
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 063709/0437 →
Continuity (3)
Continuation 16135913 · Sep 19, 2018
Provisional Application 62560955 · Sep 20, 2017
Related Publication 20230268028A1 · Aug 24, 2023
References Cited (81)
US 4863849A · Melamede · 1989 [cited by applicant]
US 4971903A · Hyman · 1990 [cited by applicant]
US 5302509A · Cheeseman · 1994 [cited by applicant]
US 5599675A · Brenner · 1997 [cited by applicant]
US 5750341A · Macevicz · 1998 [cited by applicant]
US 5763594A · Hiatt et al. · 1998 [cited by applicant]
US 5798210A · Canard et al. · 1998 [cited by applicant]
US 5939292A · Gelfand et al. · 1999 [cited by applicant]
US 6001566A · Canard et al. · 1999 [cited by applicant]
US 6090549A · Mirzabekov et al. · 2000 [cited by applicant]
US 6210891B1 · Nyren et al. · 2001 [cited by applicant]
US 6258568B1 · Nyren · 2001 [cited by applicant]
US 6401267B1 · Drmanac · 2002 [cited by applicant]
US 6620584B1 · Chee et al. · 2003 [cited by applicant]
US 6664079B2 · Ju et al. · 2003 [cited by applicant]
US 6984720B1 · Korman et al. · 2006 [cited by applicant]
US 7034121B2 · Carreno et al. · 2006 [cited by applicant]
US 7057026B2 · Barnes et al. · 2006 [cited by applicant]
US 7605238B2 · Korman et al. · 2009 [cited by applicant]
US 11640848B2 · Lim · 2023 [cited by examiner]
US 20050037398A1 · Gelfand et al. · 2005 [cited by applicant]
US 20050130173A1 · Leamon et al. · 2005 [cited by applicant]
US 20060134633A1 · Chen et al. · 2006 [cited by applicant]
US 20090088327A1 · Rigatti et al. · 2009 [cited by applicant]
US 20090325172A1 · Milton et al. · 2009 [cited by applicant]
US 20100028885A1 · Balasubramanian et al. · 2010 [cited by applicant]
US 20150203580A1 · Papadopoulos et al. · 2015 [cited by applicant]
US 20170022273A1 · Zhou · 2017 [cited by examiner]
US 20170101472A1 · Ullman et al. · 2017 [cited by applicant]
US 20170174779A1 · Varghese et al. · 2017 [cited by applicant]
CN 105777906 · 2016 [cited by applicant]
CN 106977602 · 2017 [cited by applicant]
JP 2017507650 · 2017 [cited by applicant]
WO 0123411 · 2001 [cited by applicant]
WO 05024010 · 2005 [cited by applicant]
WO 2015103037 · 2015 [cited by applicant]
WO 2017062888 · 2017 [cited by applicant]
WO 2017112775 · 2017 [cited by applicant]
WO 2017151517 · 2017 [cited by applicant]
WO 2017151524 · 2017 [cited by applicant]
WO 2018068028 · 2018 [cited by applicant]
Mishra et al (Oncotarget, 2016, 7(49): 81341-81356). [cited by examiner]
Berrien-Elliott et al (Cancer Research, 2013, 73(2): 605-616). [cited by examiner]
Office Action was mailed on Jun. 24, 2021 by the KR Patent Office for KR Application No. 10-2020-7018681, filed on Jun. 29, 2020 (Applicant—Regeneron Pharmaceuticals, Inc.). [cited by applicant]
Office Action was mailed on Feb. 23, 2022 by the KR Patent Office for KR Application No. 10-2020-7018681, filed on Jun. 29, 2020 (Applicant—Regeneron Pharmaceuticals, Inc.). [cited by applicant]
Office Action was mailed on Jun. 17, 2022 by the UA Patent Office for UA Application No. 202002442, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (3 pages). [cited by applicant]
Spencer et al., “Biomarkers for immunotherapy: current developments and challenges”, Am Soc Clin Educ Book, May 2016, 35, pp. e493-e503. [cited by applicant]
Beasley et al., “Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma”, Clinical Skin Cancer, 2016, 1(2), pp. 75-81. [cited by applicant]
Postow et al., “Immune Checkpoint Blockade in Cancer Therapy”, J of Clinical Oncology, 2015, 33(17), pp. 1974-1982. [cited by applicant]
Sharma et al., “The future of immune checkpoint therapy”, Science, 2015, 348(6230), pp. 56-61. [cited by applicant]
Migden, “PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma”, The New England Journal of Medicine, 2018, pp. 341-351. [cited by applicant]
Office Action was mailed on Mar. 21, 2022 by the CA Patent Office for CA Application No. 3,075,927, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (6 pages). [cited by applicant]
Notification of Reasons for Rejection were mailed on Jul. 20, 2021 by the JP Patent Office for JP Application No. 2020-516633, filed on Sep. 19, 2019 (Applicant—Regeneron Pharmaceuticals, Inc.) (4 pages). [cited by applicant]
Nakatsura, “Era of cancer immunotherapy has come”, Japanese J of Clinical Immunology, 2016, 39(3), pp. 164-171 (abstract). [cited by applicant]
Topalian et al., “Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy”, Nature Reviews Cancer, 2016, 16, pp. 275-287. [cited by applicant]
Topalian et al., “Immunotherapy: The path to win the war on cancer?”, Cell, 2015, 16(2), pp. 185-186. [cited by applicant]
Written Opinion and Search Report were mailed on Nov. 29, 2021 by the SG Patent Office for SG Application No. 11202002282, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (6 pages of Written Opinion; … [cited by applicant]
Decision of Refusal was mailed on Nov. 15, 2021 by the RU Patent Office for RU Application No. 2020113600, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (7 pages of Translation). [cited by applicant]
Examination Report was mailed on Nov. 10, 2021 by the AU Patent Office for AU Application No. 2018336785, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (3 pages). [cited by applicant]
Examination Report was mailed on Jul. 7, 2021 by the AU Patent Office for AU Application No. 2018336785, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (5 pages). [cited by applicant]
Office Action was mailed on Apr. 7, 2021 by the CA Patent Office for CA Application No. 3,075,927, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (5 pages). [cited by applicant]
Office Action was mailed on Jan. 3, 2022 by the CA Patent Office for CA Application No. 3,075,927, filed on Sep. 19, 2018 (Applicant—Regeneron Pharmaceuticals, Inc.) (4 pages). [cited by applicant]
Topalian et al., “Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy”, Nature Reviews Cancer, 2016, 16(5), pp. 275-287. [cited by applicant]
Campesato et al., “Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice”, Oncotarget, 2015. Retrieved from the Internet: URL: https:… [cited by applicant]
Li et al., “Mining the coding and non-coding genome for cancer drivers”, Cancer Letters, 2015, 369(2), pp. 307-315. [cited by applicant]
Mcfarland et al., “The Damaging Effect of Passenger Mutations on Cancer Progression”, Cancer Res, 2017, 77 (18), pp. 4763-4772. [cited by applicant]
Charoentong et al., “Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade”, Cell Reports, 2017, 18(1), pp. 248-262. [cited by applicant]
International Search Report and Written Opinion were mailed on Dec. 19, 2018 by the International Searching Authority for International Application No. PCT/US2018/051755, filed on Sep. 19, 2019 (Applicant—Regeneron Phar… [cited by applicant]
Altschul et al., “Issues in searching molecular sequence databases”, Nature Genet, 1994, 6(2), pp. 119-129. [cited by applicant]
Corpet et al., “Multiple sequence alignment with hierarchical clustering”, Nucl Acids Res, 1988, 16, pp. 10881-10890. [cited by applicant]
Dressman et al., “Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations”, Proc Natl Acad Sci, 2003, 100, pp. 8817-8822. [cited by applicant]
Higgins et al., “Fast and sensitive multiple sequence alignments on a microcomputer”, CABIOS, 1989, 5, pp. 151-153. [cited by applicant]
Huang et al., “Parallelization of a local Similarity Search Algorithm”, Comput Appl Biosci, 1992, 8(2), pp. 155-165. [cited by applicant]
Mitra et al., “Digital genotyping and haplotyping with polymerase colonies”, Proc Natl Acad Sci, 2003, 100(10), pp. 5926-5931. [cited by applicant]
Pearson et al., “Improved tools for biological sequence comparison”, Proc Natl Acad Sci, 1988, 85(8), pp. 2444-2448. [cited by applicant]
Ronaghi et al., “A sequencing method based on real-time pyrophosphate”, Science, 1998, 281, pp. 363. [cited by applicant]
Shendure et al., “Accurate multiplex polony sequencing of an evolved bacterial genome”, Science, 2005, 309(5741), pp. 1728-1732. [cited by applicant]
Smith et al., “Comparison of biosequences”, Advances in Applied Mathematics, 1981, 2(4), pp. 482-489. [cited by applicant]
Stratton et al., “The cancer genome”, Nature, 2009, 458(7239), pp. 719-724. [cited by applicant]
Rizvi et al., “Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer”, Science, 2015, 348(6230), pp. 124-128. [cited by applicant]
Yarchoan et al., “Targeting neoantigens to augment antitumour immunity”, Nat Rev Cancer, 2017, 17(4), pp. 209-222. [cited by applicant]
Cited By (1)
US 12,721,914